<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342314</url>
  </required_header>
  <id_info>
    <org_study_id>15503</org_study_id>
    <secondary_id>I7U-MC-GAHA</secondary_id>
    <nct_id>NCT02342314</nct_id>
  </id_info>
  <brief_title>A Study of LY3143753 and LY3185643 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves a single dose of LY3143753 or LY3185643, given as an injection into the
      abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The
      study is approximately 12 weeks for each participant, not including screening. Screening is
      required within 28 days prior to the start of the study. This study involves Part A
      (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose
      level.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (Up to 84 Days)</time_frame>
    <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC(0-∞) of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Drug Concentration (Tmax) of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Tmax of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD): Absolute Maximum Blood Glucose of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Absolute Maximum Blood Glucose of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Maximum Glucose Increase (Gmax) of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Gmax of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Time to Maximum Blood Glucose (Gtmax) of Part A</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Gtmax of Part B</measure>
    <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT Interval as Corrected by the Fridericia Method (QTcF) Change From Baseline of Part A</measure>
    <time_frame>Baseline, 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF Change From Baseline of Part B</measure>
    <time_frame>Baseline, 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3143753 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3185643 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of ascending doses of LY3185643 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single SC injection of normal saline on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rGlucagon (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single SC injection on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single SC injection of normal saline on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3143753 (Part A)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY3143753 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3185643 (Part B)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY3185643 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part A and Part B)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rGlucagon (Part B)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>rGlucagon (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

        Exclusion Criteria:

          -  Are investigator site personnel directly affiliated with this study and their
             immediate families

          -  Are currently enrolled in a clinical trial involving an investigational product (IP)
             or off-label use of a drug or device

          -  Have participated, within the last 3 months, in a clinical trial

          -  Have known or ongoing psychiatric disorders

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  History of/current phaeochromocytoma

          -  History of/current insulinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <results_first_submitted>February 17, 2018</results_first_submitted>
  <results_first_submitted_qc>March 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2019</results_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part A)</title>
          <description>Single subcutaneous (SC) injection of normal saline on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>0.05 mg of LY3143753 (Part A)</title>
          <description>Part A: 0.05 milligram (mg) of LY3143753 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>0.1 mg of LY3143753 (Part A)</title>
          <description>Part A: 0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>0.2 mg of LY3143753 (Part A)</title>
          <description>Part A: 0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>0.4 mg of LY3143753 (Part A)</title>
          <description>Part A: 0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>1.0 mg of LY3143753 (Part A)</title>
          <description>Part A: 1.0 mg of LY3143753 given as a SC injection on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Placebo (Part B)</title>
          <description>Part B: Single SC injection of normal saline on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>0.01 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P9">
          <title>0.03 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P10">
          <title>0.05 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P11">
          <title>0.06 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P12">
          <title>0.1 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P13">
          <title>0.2 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P14">
          <title>0.3 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P15">
          <title>0.48 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P16">
          <title>0.72 mg of LY3185643 (Part B)</title>
          <description>Part B: 0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="P17">
          <title>rGlucagon (Part B)</title>
          <description>Part B: 1.0 mg of rGlucagon given as a single SC injection. (Part B).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants received placebo in Part A.</participants>
                <participants group_id="P2" count="0">Participants received LY3143753 in Part A.</participants>
                <participants group_id="P3" count="0">Participants received LY3143753 in Part A.</participants>
                <participants group_id="P4" count="0">Participants received LY3143753 in Part A.</participants>
                <participants group_id="P5" count="0">Participants received LY3143753 in Part A.</participants>
                <participants group_id="P6" count="0">Participants received LY3143753 in Part A.</participants>
                <participants group_id="P7" count="11">Participants received placebo in Part B.</participants>
                <participants group_id="P8" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P9" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P10" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P11" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P12" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P13" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P14" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P15" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P16" count="3">Participants received LY3185643 in Part B.</participants>
                <participants group_id="P17" count="6">Participants received rGlucagon in Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY3143753 (Part A)</title>
          <description>Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>LY3185643 (Part B)</title>
          <description>Single SC injection of ascending doses of LY3185643 on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
        <time_frame>Baseline to Study Completion (Up to 84 Days)</time_frame>
        <population>All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection.</description>
          </group>
          <group group_id="O3">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection.</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection.</description>
          </group>
          <group group_id="O5">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection.</description>
          </group>
          <group group_id="O6">
            <title>1 mg of LY3143753 (Part A)</title>
            <description>1 mg of LY3143753 given as a single SC injection.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part B)</title>
            <description>Single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O11">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O12">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O13">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O14">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O15">
            <title>Part B 0.48 mg of LY3185643</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O16">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O17">
            <title>r Glucagon (Part B)</title>
            <description>1 mg of rGlucagon given as a single SC injection. (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
          <population>All randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="3"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.726" spread="81"/>
                    <measurement group_id="O2" value="1.05" spread="73"/>
                    <measurement group_id="O3" value="2.95" spread="13"/>
                    <measurement group_id="O4" value="5.73" spread="47"/>
                    <measurement group_id="O5" value="11.4" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" spread="12"/>
                    <measurement group_id="O2" value="0.367" spread="51"/>
                    <measurement group_id="O3" value="1.19" spread="70"/>
                    <measurement group_id="O4" value="0.951" spread="32"/>
                    <measurement group_id="O5" value="2.34" spread="48"/>
                    <measurement group_id="O6" value="4.25" spread="53"/>
                    <measurement group_id="O7" value="4.67" spread="51"/>
                    <measurement group_id="O8" value="6.49" spread="58"/>
                    <measurement group_id="O9" value="9.67" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="46"/>
                    <measurement group_id="O2" value="1.57" spread="97"/>
                    <measurement group_id="O3" value="5.76" spread="38"/>
                    <measurement group_id="O4" value="12.6" spread="33"/>
                    <measurement group_id="O5" value="22.6" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: AUC(0-∞) of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC(0-∞) of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">PK data from 3 participants at this lowest LY3185643 dose was very limited with few measurable data points which led to the inability to estimate the AUC(0-infinity) PK parameter.</measurement>
                    <measurement group_id="O2" value="0.564" spread="8"/>
                    <measurement group_id="O3" value="2.61" spread="42"/>
                    <measurement group_id="O4" value="1.34" spread="24"/>
                    <measurement group_id="O5" value="3.73" spread="22"/>
                    <measurement group_id="O6" value="8.87" spread="18"/>
                    <measurement group_id="O7" value="10.8" spread="14"/>
                    <measurement group_id="O8" value="16.2" spread="55"/>
                    <measurement group_id="O9" value="21.5" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Time to Maximum Drug Concentration (Tmax) of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time to Maximum Drug Concentration (Tmax) of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.67" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.33" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.67" lower_limit="0.67" upper_limit="0.67"/>
                    <measurement group_id="O4" value="1.04" lower_limit="0.67" upper_limit="1.50"/>
                    <measurement group_id="O5" value="1.25" lower_limit="0.67" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Tmax of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4, 6, 8 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Tmax of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.83" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.83" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.67" lower_limit="0.55" upper_limit="0.83"/>
                    <measurement group_id="O5" value="0.50" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.25" lower_limit="1.00" upper_limit="1.25"/>
                    <measurement group_id="O7" value="1.23" lower_limit="0.83" upper_limit="1.25"/>
                    <measurement group_id="O8" value="1.75" lower_limit="0.67" upper_limit="1.75"/>
                    <measurement group_id="O9" value="0.83" lower_limit="0.67" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic (PD): Absolute Maximum Blood Glucose of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All participants who received at least one dose of study drug or placebo and have evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic (PD): Absolute Maximum Blood Glucose of Part A</title>
          <population>All participants who received at least one dose of study drug or placebo and have evaluable PD data.</population>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="10"/>
                    <measurement group_id="O2" value="168" spread="26"/>
                    <measurement group_id="O3" value="197" spread="17"/>
                    <measurement group_id="O4" value="179" spread="13"/>
                    <measurement group_id="O5" value="188" spread="10"/>
                    <measurement group_id="O6" value="177" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Absolute Maximum Blood Glucose of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All participants who received at least one dose of study drug or placebo and have evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part B)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>Part B 0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O11">
            <title>1.0 mg of rGlucagon (Part B)</title>
            <description>1.0 mg of rGlucagon given as a single SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Absolute Maximum Blood Glucose of Part B</title>
          <population>All participants who received at least one dose of study drug or placebo and have evaluable PD data.</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" spread="5"/>
                    <measurement group_id="O2" value="103" spread="11"/>
                    <measurement group_id="O3" value="98.1" spread="10"/>
                    <measurement group_id="O4" value="128" spread="36"/>
                    <measurement group_id="O5" value="117" spread="7"/>
                    <measurement group_id="O6" value="167" spread="16"/>
                    <measurement group_id="O7" value="186" spread="7"/>
                    <measurement group_id="O8" value="146" spread="16"/>
                    <measurement group_id="O9" value="192" spread="16"/>
                    <measurement group_id="O10" value="188" spread="3"/>
                    <measurement group_id="O11" value="162" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Maximum Glucose Increase (Gmax) of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Maximum Glucose Increase (Gmax) of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="112"/>
                    <measurement group_id="O2" value="66.1" spread="63"/>
                    <measurement group_id="O3" value="103" spread="17"/>
                    <measurement group_id="O4" value="84.9" spread="18"/>
                    <measurement group_id="O5" value="91.5" spread="20"/>
                    <measurement group_id="O6" value="79.8" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Gmax of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part B)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O11">
            <title>1.0 mg of rGlucagon (Part B)</title>
            <description>1.0 mg of rGlucagon given as a single SC injection. (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Gmax of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="54"/>
                    <measurement group_id="O2" value="7.2" spread="12.6"/>
                    <measurement group_id="O3" value="5.04" spread="189"/>
                    <measurement group_id="O4" value="28.1" spread="144"/>
                    <measurement group_id="O5" value="21.8" spread="66"/>
                    <measurement group_id="O6" value="76.1" spread="35"/>
                    <measurement group_id="O7" value="89.4" spread="14"/>
                    <measurement group_id="O8" value="58.4" spread="35"/>
                    <measurement group_id="O9" value="102" spread="25"/>
                    <measurement group_id="O10" value="105" spread="6"/>
                    <measurement group_id="O11" value="71.8" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Time to Maximum Blood Glucose (Gtmax) of Part A</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.1 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Time to Maximum Blood Glucose (Gtmax) of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.58" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.67" lower_limit="0.5" upper_limit="0.67"/>
                    <measurement group_id="O5" value="0.79" lower_limit="0.75" upper_limit="2.5"/>
                    <measurement group_id="O6" value="0.58" lower_limit="0.50" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Gtmax of Part B</title>
        <time_frame>Predose, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 550, 60, 70, 80, 90, 105, minutes and 2, 2.5, 3, 4 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part B)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O11">
            <title>1.0 mg of rGlucagon (Part B)</title>
            <description>1.0 mg of rGlucagon given as a single SC injection. (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Gtmax of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PD data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.67" lower_limit="0.25" upper_limit="0.83"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.83" upper_limit="1.33"/>
                    <measurement group_id="O5" value="0.67" lower_limit="0.67" upper_limit="0.75"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.75" upper_limit="1.17"/>
                    <measurement group_id="O7" value="1.17" lower_limit="0.92" upper_limit="1.33"/>
                    <measurement group_id="O8" value="0.58" lower_limit="0.5" upper_limit="0.75"/>
                    <measurement group_id="O9" value="1.17" lower_limit="0.83" upper_limit="1.33"/>
                    <measurement group_id="O10" value="0.75" lower_limit="0.67" upper_limit="1.0"/>
                    <measurement group_id="O11" value="0.46" lower_limit="0.33" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT Interval as Corrected by the Fridericia Method (QTcF) Change From Baseline of Part A</title>
        <time_frame>Baseline, 8 hours after drug administration</time_frame>
        <population>All randomized participants who received at least one dose of study drug and who had evaluable QTcF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.05 mg of LY3143753 (Part A)</title>
            <description>0.05 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.1 mg of LY3143753 (Part A)</title>
            <description>0.01 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg of LY3143753 (Part A)</title>
            <description>0.2 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.4 mg of LY3143753 (Part A)</title>
            <description>0.4 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>1.0 mg of LY3143753 (Part A)</title>
            <description>1.0 mg of LY3143753 given as a single SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>QT Interval as Corrected by the Fridericia Method (QTcF) Change From Baseline of Part A</title>
          <population>All randomized participants who received at least one dose of study drug and who had evaluable QTcF data.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="6.4"/>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not available for one participant at each of these time points so the mean and standard deviation (SD) were not applicable.</measurement>
                    <measurement group_id="O3" value="0.2" spread="18.6"/>
                    <measurement group_id="O4" value="NA" spread="NA">Data was not available for one participant at each of these time points so the mean and SD were not applicable.</measurement>
                    <measurement group_id="O5" value="6.1" spread="14.5"/>
                    <measurement group_id="O6" value="6.1" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF Change From Baseline of Part B</title>
        <time_frame>Baseline, 8 hours after drug administration</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable QTcF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part B)</title>
            <description>Single SC injection of normal saline on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg of LY3185643 (Part B)</title>
            <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg of LY3185643 (Part B)</title>
            <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>0.05 mg of LY3185643 (Part B)</title>
            <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>0.06 mg of LY3185643 (Part B)</title>
            <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>0.1 mg of LY3185643 (Part B)</title>
            <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>0.2 mg of LY3185643 (Part B)</title>
            <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>0.3 mg of LY3185643 (Part B)</title>
            <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>0.48 mg of LY3185643 (Part B)</title>
            <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O10">
            <title>0.72 mg of LY3185643 (Part B)</title>
            <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
          </group>
          <group group_id="O11">
            <title>rGlucagon (Part B)</title>
            <description>1 mg of rGlucagon given as a single SC injection. (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF Change From Baseline of Part B</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable QTcF data.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="8.3"/>
                    <measurement group_id="O2" value="-2.9" spread="8.5"/>
                    <measurement group_id="O3" value="-10.2" spread="3.3"/>
                    <measurement group_id="O4" value="-5.9" spread="12.5"/>
                    <measurement group_id="O5" value="-4.1" spread="7.8"/>
                    <measurement group_id="O6" value="0.5" spread="11.3"/>
                    <measurement group_id="O7" value="-4.7" spread="7.6"/>
                    <measurement group_id="O8" value="2.5" spread="13.0"/>
                    <measurement group_id="O9" value="-2.1" spread="2.7"/>
                    <measurement group_id="O10" value="NA" spread="NA">Data was not available for one participant at each of these time points so the mean and SD were not applicable.</measurement>
                    <measurement group_id="O11" value="-7.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part A)</title>
          <description>Single SC injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>0.05 mg of LY3143753 (Part A)</title>
          <description>0.05 mg of LY3143753 given as a single SC injection.</description>
        </group>
        <group group_id="E3">
          <title>0.1 mg of LY3143753 (Part A)</title>
          <description>0.1 mg of LY3143753 given as a single SC injection.</description>
        </group>
        <group group_id="E4">
          <title>0.2 mg of LY3143753 (Part A)</title>
          <description>0.2 mg of LY3143753 given as a single SC injection.</description>
        </group>
        <group group_id="E5">
          <title>0.4 mg of LY3143753 (Part A)</title>
          <description>0.4 mg of LY3143753 given as a single SC injection.</description>
        </group>
        <group group_id="E6">
          <title>1 mg of LY3143753 (Part A)</title>
          <description>1 mg of LY3143753 given as a single SC injection.</description>
        </group>
        <group group_id="E7">
          <title>Placebo (Part B)</title>
          <description>Single SC injection on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>0.01 mg of LY3185643 (Part B)</title>
          <description>0.01 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>0.03 mg of LY3185643 (Part B)</title>
          <description>0.03 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E10">
          <title>0.05 mg of LY3185643 (Part B)</title>
          <description>0.05 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E11">
          <title>0.06 mg of LY3185643 (Part B)</title>
          <description>0.06 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E12">
          <title>0.1 mg of LY3185643 (Part B)</title>
          <description>0.1 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E13">
          <title>0.2 mg of LY3185643 (Part B)</title>
          <description>0.2 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E14">
          <title>0.3 mg of LY3185643 (Part B)</title>
          <description>0.3 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E15">
          <title>Part B 0.48 mg of LY3185643</title>
          <description>0.48 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E16">
          <title>0.72 mg of LY3185643 (Part B)</title>
          <description>0.72 mg of LY3185643 given as a single SC injection on Day 1.</description>
        </group>
        <group group_id="E17">
          <title>r Glucagon (Part B)</title>
          <description>1 mg of rGlucagon given as a single SC injection. (Part B).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" events="5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

